Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Gains from Investment Securities (2020 - 2025)

Historic Gains from Investment Securities for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to $10.4 million.

  • Tarsus Pharmaceuticals' Gains from Investment Securities rose 4184400.0% to $10.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.3 million, marking a year-over-year increase of 176954.4%. This contributed to the annual value of -$572000.0 for FY2024, which is 13098.59% down from last year.
  • Per Tarsus Pharmaceuticals' latest filing, its Gains from Investment Securities stood at $10.4 million for Q3 2025, which was up 4184400.0% from -$102000.0 recorded in Q2 2025.
  • Over the past 5 years, Tarsus Pharmaceuticals' Gains from Investment Securities peaked at $10.4 million during Q3 2025, and registered a low of -$3.2 million during Q4 2021.
  • Its 5-year average for Gains from Investment Securities is $997357.1, with a median of $65500.0 in 2022.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first tumbled by 15624.28% in 2024, then surged by 4184400.0% in 2025.
  • Tarsus Pharmaceuticals' Gains from Investment Securities (Quarter) stood at -$3.2 million in 2021, then soared by 104.34% to $140000.0 in 2022, then surged by 1135.71% to $1.7 million in 2023, then crashed by 97.57% to $42000.0 in 2024, then surged by 24747.62% to $10.4 million in 2025.
  • Its Gains from Investment Securities was $10.4 million in Q3 2025, compared to -$102000.0 in Q2 2025 and -$125000.0 in Q1 2025.